Malaria vaccine - GenVec/Naval Medical Research Center

Drug Profile

Malaria vaccine - GenVec/Naval Medical Research Center

Alternative Names: DNA-Ad; NMRC-M3V-Ad-PfCA vaccine

Latest Information Update: 15 Sep 2015

Price : $50

At a glance

  • Originator GenVec; Naval Medical Research Center
  • Class Antimalarials; Parasitic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Malaria

Most Recent Events

  • 15 Sep 2015 No recent reports on development identified - Phase-I/II for Malaria (Prevention, In volunteers) in USA (Parenteral)
  • 26 Mar 2012 GenVec receives grant from NIAID of the NIH for malaria vaccine development in Malaria
  • 22 Jun 2011 Naval Medical Research Center completes enrolment in its phase I/II trial for Malaria in US (NCT00392015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top